Who is affected by this change?

This affects Independence Blue Cross Rheumatology, Dermatology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Apr 29, 2026.

Back to dashboard

Medicare AdvantageCoverageLow impact

MA08.140c, Anifrolumab-fnia (Saphnelo®)

Independence Blue Cross·Rheumatology, Dermatology·Pharmacy

Effective date

Apr 29, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.140c for Anifrolumab-fnia (Saphnelo®) has been reissued with an effective date of April 29, 2026. This appears to be a pharmacy policy update, though specific coverage or billing changes are not detailed in the summary provided.

Action Required

Action needed

By April 29, 2026: Billing team should review the full policy details at the provided URL to understand any changes to coverage, prior authorization, or billing requirements for Anifrolumab-fnia (Saphnelo®). Update pharmacy billing protocols as needed based on the complete policy content.

Related policy hubs

Independence Blue Cross policies Rheumatology Dermatology